Brentuximab vedotin, nivolumab, and chemotherapy in classical Hodgkin lymphoma; type 1 interferon signaling in sickle cell disease; and type 1 human leukocyte antigen gene mutations in cutaneous T-cell lymphoma

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

NPR News: 09-24-2026 11PM EDT 5 min · 25 Sep 2026 · NPR News Now

Microsoft AI Boss: “A Silicon Species” Could Compete With HumansMicrosoft AI Boss: “A Silicon Species” Could Compete With Humans 38 min · 25 Sep 2026 · AI Haven't A Clue

Who are the "passport bros" travelling abroad to find love? 5 min · 25 Sep 2026 · Do you really know?

Can plate colour really affect our sense of taste? 5 min · 25 Sep 2026 · Do you really know?

Is a white tongue unhealthy? 2 min · 25 Sep 2026 · Do you really know?

After 2 Years of Interviewing Health Experts, Here’s What I Actually Believe 58 min · 25 Sep 2026 · Culture Apothecary with Alex Clark

Report any issue

Source

Recorded16 Jan 2025

Publisherfeeds.transistor.fm ↗

Handlerec:11741931

Show notes

In this week's episode we’ll learn more about an experimental regimen for classical Hodgkin lymphoma that combines brentuximab vedotin, nivolumab, and chemotherapy; a possible role for type 1 interferon signaling in developing autoantibodies to red blood cells in sickle cell disease; and how genomic alterations affecting class I human leukocyte antigen molecules may affect patients with cutaneous T-cell lymphoma. Featured Articles:Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphomaIFN-I promotes T-cell–independent immunity and RBC autoantibodies via modulation of B-1 cell subsets in murine SCDGenetic alteration of class I HLA in cutaneous T-cell lymphoma

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in